Humacyte, Inc. - Common Stock HUMA 深 滬
交易中 10-03 10:39:15 美东时间
1.885
+0.095
+5.31%
華盛通- 最 高1.93
- 今 開1.81
- 成交量 139.23万股
- 最 低 1.79
- 昨 收 1.79
- 總市值 3.00亿
- 52周最高 6.77
- 市盈率 靜 --
- 換手率 0.88%
- 52周最低 1.15
- 委 比 60.10%
- 總股本 1.59亿
- 歷史最高 17.45
- 量 比 4.85
- 振 幅 7.82%
- 歷史最低 1.15
- 每 手 1
- 風險率 1.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Humacyte Secures U.S. Patent For Bioengineered Esophagus Composition Using Proprietary Regenerative Tissue Engineering Platform
– Patent covers esophagus produced using Humacyte's proprietary bioengineered regenerative tissue platform, designed for implant in patients with damaged esophagus –– Patent provides coverage into 2041 for the composition of novel bioengineered esophagus –
09-29 20:16
Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus
Humacyte, Inc. has been granted a U.S. patent for a bioengineered esophagus produced using its proprietary regenerative tissue engineering platform, offering protection until 2041. This expands the company's patent coverage for bioengineered trachea, esophagus, and urinary conduits in multiple regions, including the U.S., Europe, Canada, and Australia. The advanced tissue constructs are part of Humacyte's broad product pipeline and are currently ...
09-29 12:00
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff.
09-19 03:08
Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)
Humacyte announced positive preclinical results for its coronary tissue engineered vessel (CTEV) in a non-human primate model, showing sustained patency, adaptive remodeling, and recellularization with host cells. The CTEV, designed as an alternative to traditional grafts, demonstrated potential superiority in reducing size mismatch and improving long-term outcomes. Humacyte plans to advance CTEV into first-in-human studies, with an IND applicati...
09-18 11:00
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
D. Boral Capital Maintains Buy on Humacyte, Maintains $25 Price Target
D. Boral Capital analyst Jason Kolbert maintains Humacyte (NASDAQ:HUMA) with a Buy and maintains $25 price target.
09-15 21:27
Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™
Humacyte, Inc. announced the publication of outcomes for patients with hospital-acquired vascular complications treated with Symvess in the Journal of Vascular Surgery. The study reported 12 patients with hospital-acquired iatrogenic injuries or complications of vascular surgical procedures. Symvess demonstrated high patency (92% maintained secondary patency at an average follow-up of 23.3 months), 100% limb salvage, and zero cases of conduit inf...
09-15 11:00
美股大行评级 | 最高至425美元！MONGODB获多家机构上调目标价；德银上调回声星通信(SATS)目标价升至67美元
今日重点评级关注：Oppenheimer：维持Chemomab Therapeutics"跑赢大市"评级，目标价从10美元升至25美元；花旗：维持MongoDB"买入"评级，目标价从405美元升至425美元
08-28 09:51
Humacyte, Senseonics jump as Barclays issues new Overweight ratings
Bioengineered tissue maker Humacyte (NASDAQ:HUMA) and Senseonics (NYSE:SENS), a developer of continuous glucose monitoring (CGM) devices, traded higher on Wednesday after Barclays initiated their cove...
08-27 22:24
